These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1710750)

  • 21. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
    Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
    Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
    van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
    Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
    Teillac P; Delauche-Cavallier MC; Attali P
    Br J Urol; 1992 Jul; 70(1):58-64. PubMed ID: 1379106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
    Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
    Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
    Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.
    Lukacs B; Blondin P; MacCarthy C; Du Boys B; Grippon P; Lassale C
    Eur Urol; 1996; 29(1):29-35. PubMed ID: 8821687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.